RxSight reported second quarter 2026 total revenue of $33.7 million, including $6.5 million from a strategic collaboration with Alcon, while product sales declined 19% year-over-year to $27.2 million due to competitive pressure. The company appointed Aziz Mottiwala as President and CEO and withdrew its 2026 financial guidance to allow for a comprehensive business review ahead of resuming formal guidance in early 2027. Net loss was $12.1 million, or $0.29 per share, compared to a net loss of $11.8 million in the prior year period. The company holds approximately $209 million in cash and short-term investments as of June 30, 2026. RxSight operates in the ophthalmic medical device industry, specializing in light-adjustable intraocular lenses for cataract surgery.

RxSight, Inc. announced a leadership transition effective July 20, 2026, appointing Aziz Mottiwala as President and Chief Executive Officer, replacing Ron Kurtz, M.D., who will transition to Chief Medical Officer and resign from the Board. Mr. Mottiwala will receive an annual base salary of $750,000 and $14,000,000 in equity awards. Dr. Kurtz will receive a retention bonus of $370,000 on four specific dates through 2028 and 500,000 RSUs. RxSight, Inc. is an ophthalmic medical device company specializing in light-adjustable intraocular lens technology.

RxSight, Inc. entered into a License, Collaboration and Development Agreement with Alcon Pharmaceuticals, Ltd to develop and commercialize light-adjustable versions of certain Alcon simultaneous vision intraocular lenses. The agreement includes a $60 million upfront cash payment to RxSight, with potential milestone payments of $70 million for feasibility, $30 million for FDA submission, and $40 million for regulatory approval, plus 30% royalties on net sales. RxSight, Inc. is a medical technology company that develops and commercializes light-adjustable intraocular lenses for ophthalmic surgery.